0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-147.52%PremiumDec 20, 2024Expiry Date1.49Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cytosorbents Stock Discussion
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents (NASDAQ: CTSO) and Converge Biotech have announced a strategic partnership to expand their market reach in India's sepsis and critical care markets. CytoSorbents' flagship product, CytoSorb, a blood purification technology that reduces cytokine storm and inflammatory toxins, will be distributed through Converge Biotech's ext...
📊⚡️📊
NEWS
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
No comment yet